Central Alerting System
View Alert

Originator: CMO Messaging

From: CMO Messaging

Issue date: Originally issued on 21-Feb-2024 13:57:16. This version was issued on 21-Feb-2024 13:57:16

This alert has been issued to:
  • Care Trusts
  • Mental Health Trusts
  • Other contacts
  • Specialists Trusts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • NHS Regional Offices
  • Learning Disabilities Trusts
  • Mental Health & Social Care Trusts
  • Ambulance Trusts
  • Social Care Providers (registered with CAS)
  • Mental Health & Learning Disabilities Trusts
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • Regional Directors of Public Health
  • Director of Public Health
  • Acute Trusts
  • Community Trusts
  • GP - Locum
  • NHS 111 and Out of hours providers
  • GP Practices
  • Integrated Care Boards
  • Community Pharmacy
  • Primary Care Networks
  • GP Practices 1

Action category: Action

Title: Valproate: important new regulatory measures for oversight of prescribing to new patients and existing female patients

Broadcast content:

The harmful effects of prenatal exposure to valproate are well documented. Following a review, the Commission on Human Medicines has recommended further restrictions to valproate use to reduce avoidable harm which were introduced by the MHRA in January.

Please see the attached letter from Chief Medical Officers across the UK regarding the recently announced sodium valproate safety measures.

Additional information: NHS England Regions: please cascade this notification to community pharmacy.

Alert reference: CEM/CMO/2024/001


Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency